Journal
AUSTRALIAN PRESCRIBER
Volume 39, Issue 4, Pages 131-134Publisher
NATL PRESCRIBING SERVICE LTD
DOI: 10.18773/austprescr.2016.053
Keywords
antineoplastic agent; antineutrophil cytoplasmic antibody; autoantibody; B lymphocyte; lymphoma; rituximab
Categories
Ask authors/readers for more resources
Rituximab is a monoclonal antibody that depletes B cells from the circulation. It was originally used to treat lymphoma but is increasingly used for the treatment of autoimmune diseases. Rituximab was found to be effective in randomised controlled trials for rheumatoid arthritis, granulomatosis with polyangiitis and other antineutrophil cytoplasmic antibody-associated vasculitides. However, evidence of efficacy is very limited for many other autoimmune conditions. Before starting rituximab, it is important to check the patient's baseline immunoglobulins and immunisation status. Patients should also be screened for latent infections and other contraindications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available